EMORRAGIA DA VARICI GASTRICHE: MEGLIO PIU’ CIANOACRILATO ? O NO? UN TRIAL SU 145 PAZIENTI: CHIUSURA TUTTE VARICI O SOLO VARICI CON SEGNI DI RECENTE EMORRAGIA? DA “ENDOSCOPY”

ENDOSCOPIA, EPATOLOGIA, GASTROENTEROLOGIA, NEWSLETTER

Aggressive versus conservative endotherapy for gastric varices in cirrhosis: a randomized controlled trial Ritesh Prajapati et al. Abstract Gastric variceal bleeding in cirrhosis remains a challenging clinical problem with variations in management strategies. This randomized controlled trial compared aggressive versus conservative cyanoacrylate therapy for gastric varices in patients with cirrhosis presenting with their first variceal…

EMORRAGIA DA VARICI GASTRICHE: MEGLIO PIU’ CIANOACRILATO ? O NO? UN OTTIMO EDITORIALE DA “ENDOSCOPY” SULL’ARTICOLO DI Ritesh Prajapati et al. doi: 10.1055/a-2639-1875

ENDOSCOPIA, GASTROENTEROLOGIA, NEWSLETTER

Aggressive or conservative cyanoacrylate therapy for gastric varices: is more glue better? EDITORIALE DI Marine Camus Gastric variceal bleeding remains one of the most severe complications of portal hypertension. While cyanoacrylate injection has become established as the cornerstone of endoscopic treatment for gastric varices, an important clinical question remains: should endoscopists inject glue into every…

ESOFAGITE EOSINOFILA : 3 ARTICOLI 2025 DI RILIEVO! DA “World Gastroenterology Organisation” (FREE)

ENDOSCOPIA, GASTROENTEROLOGIA, NEWSLETTER

Long-term treatment of EoE: BOS, BOT, and PPIs Review by Prof. Humphrey O’Connor (Ireland) Study Summary Eosinophilic Esophagitis (EoE) is a chronic progressive inflammatory disorder that requires ongoing treatment to maintain remission and prevent fibrostenotic complications. Three recent studies published together provide useful guidance on long-term prescribing. In a 4yr US multicentre open label continuation…

NEOPLASIE PANCREAS RESECABILI: PANCREATODUODENECTOMIA MINIMAMENTE INVASIVA VS OPEN. SAFETY FIRST ! UN GRANDE COMMENTO EDITORIALE DA “NEJM EVIDENCE” (FREE)

CHIRURGIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI, Senza categoria

Minimally Invasive Pancreatoduodenectomy — Safety First Authors: Rachel H. Joung, M.D., M.S., and Rebecca A. Snyder, M.D., M.P.H. Recent advances in surgical technology have led to increased adoption of minimally invasive pancreatectomy despite limited prospective evidence regarding the safety and efficacy of this approach. Although minimally invasive techniques may offer the potential for earlier recovery, few studies to date have directly…

NEOPLASIE PANCREAS RESECABILI: LA PANCREATODUODENECTOMIA MINIMAMENTE INVASIVA EQUIVALE ALLA OPEN. UN GRANDE TRIAL MULTICENTRICO DA 14 CENTRI SU 288 PAZIENTI. DA “NEJM EVIDENCE” (FREE)

CHIRURGIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI

Minimally Invasive versus Open Pancreatoduodenectomy for Resectable Neoplasms  Nine de Graaf, et al. Abstract Background Minimally invasive pancreatoduodenectomy (MIPD) might accelerate postoperative recovery in patients with primary resectable neoplasm compared with open pancreatoduodenectomy (OPD), although the safety of MIPD remains debated. We aimed to assess whether MIPD is noninferior to OPD for overall complications and…

CIRROSI SCOMPENSATA : NIENTE DA FARE. SIMVASTATINA + RIFAXIMINA NON MIGLIORANO GLI ESITI. UN TRIAL MULTICENTRICO DA 14 CENTRI EUROPEI SU 237 PAZIENTI. DA “JAMA” (FREE!)

EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, MEDICINA INTERNA, NEWSLETTER

Simvastatin and Rifaximin in Decompensated Cirrhosis. A Randomized Clinical Trial Elisa Pose et al. Key Points Question  Is the combination of simvastatin and rifaximin useful to prevent severe complications of liver cirrhosis? Findings  In this randomized clinical trial that included 237 patients with decompensated cirrhosis, no significant differences were found in terms of the incidence of severe…